Frazier Life Sciences Management L.P. Sells 1,900,000 Shares of BridgeBio Pharma, Inc. $BBIO

Frazier Life Sciences Management L.P. decreased its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 55.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,548,139 shares of the company's stock after selling 1,900,000 shares during the period. BridgeBio Pharma makes up 2.5% of Frazier Life Sciences Management L.P.'s investment portfolio, making the stock its 11th largest holding. Frazier Life Sciences Management L.P. owned approximately 0.79% of BridgeBio Pharma worth $115,305,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Silvant Capital Management LLC bought a new stake in BridgeBio Pharma during the 2nd quarter valued at approximately $28,000. Allworth Financial LP bought a new position in shares of BridgeBio Pharma in the 2nd quarter worth approximately $31,000. Harvest Fund Management Co. Ltd purchased a new position in shares of BridgeBio Pharma in the 3rd quarter valued at approximately $34,000. Jones Financial Companies Lllp purchased a new position in shares of BridgeBio Pharma in the 1st quarter valued at approximately $35,000. Finally, Global Retirement Partners LLC boosted its position in shares of BridgeBio Pharma by 271.5% during the fourth quarter. Global Retirement Partners LLC now owns 509 shares of the company's stock valued at $39,000 after purchasing an additional 372 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on BBIO shares. TD Cowen increased their price objective on BridgeBio Pharma from $95.00 to $110.00 and gave the stock a "buy" rating in a report on Tuesday, August 11th. Truist Financial upped their target price on shares of BridgeBio Pharma from $102.00 to $107.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. JPMorgan Chase & Co. upped their target price on shares of BridgeBio Pharma from $100.00 to $111.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 12th. HC Wainwright reiterated a "buy" rating and issued a $120.00 price target on shares of BridgeBio Pharma in a research note on Wednesday, September 2nd. Finally, Raymond James Financial cut shares of BridgeBio Pharma from an "outperform" rating to a "market perform" rating in a research report on Tuesday, May 26th. Twenty analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, BridgeBio Pharma presently has an average rating of "Moderate Buy" and an average target price of $101.53.

BridgeBio Pharma News Summary

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $120 price target, indicating that the analyst believes BridgeBio’s longer-term growth potential remains intact despite the earnings-estimate reductions. HC Wainwright Reaffirms Buy Rating for BridgeBio Pharma
• Positive Sentiment: Barclays and Cantor Fitzgerald also maintained Buy ratings on BridgeBio Pharma, providing additional analyst support for the stock. Barclays Sticks to Its Buy Rating for BridgeBio Pharma Cantor Fitzgerald Remains a Buy on BridgeBio Pharma
• Neutral Sentiment: HC Wainwright’s estimates still imply a transition from losses in 2026 to profitability in 2027, forecasting a $1.88 per-share loss for fiscal 2026 and $1.31 in earnings for fiscal 2027.
• Negative Sentiment: HC Wainwright lowered its fiscal 2026 EPS forecast to a $1.88 loss from a $1.50 loss and cut its fiscal 2027 estimate to $1.31 from $2.19. It also reduced estimates for several 2027 quarters, including Q1 to a $0.18 loss from $0.11 in earnings and Q2 to $0.19 in earnings from $0.44.
• Negative Sentiment: The estimate cuts extend to near-term results: Q3 2026 EPS was lowered to a $0.40 loss from a $0.38 loss, while Q4 2026 EPS was trimmed slightly to $0.13 from $0.14. These revisions may weigh on sentiment because they point to slower-than-previously-expected earnings progression.

Insider Buying and Selling

In related news, Director Andrea Ellis sold 17,167 shares of the stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $84.00, for a total transaction of $1,442,028.00. Following the sale, the director directly owned 22,579 shares of the company's stock, valued at approximately $1,896,636. This represents a 43.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Hannah Valantine sold 2,808 shares of the firm's stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $68.00, for a total transaction of $190,944.00. Following the sale, the director owned 11,455 shares of the company's stock, valued at approximately $778,940. This represents a 19.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 347,343 shares of company stock worth $27,591,000 over the last quarter. 14.23% of the stock is owned by insiders.

BridgeBio Pharma Stock Performance

Shares of NASDAQ:BBIO opened at $74.84 on Monday. The stock has a fifty day simple moving average of $80.74 and a two-hundred day simple moving average of $73.61. BridgeBio Pharma, Inc. has a 12-month low of $48.78 and a 12-month high of $93.42. The stock has a market capitalization of $14.63 billion, a price-to-earnings ratio of -20.96 and a beta of 0.97.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.20). The firm had revenue of $243.68 million during the quarter, compared to analysts' expectations of $220.91 million. During the same quarter in the prior year, the company posted ($0.95) earnings per share. The company's revenue was up 120.4% on a year-over-year basis. As a group, equities research analysts predict that BridgeBio Pharma, Inc. will post -2.64 EPS for the current year.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source